Loading
Drugs that destroy proteins can hit healthy cells too. Attaching them to an antibody that only docks onto tumour cells would keep them where they are needed.
Degrader-antibody conjugates replace cytotoxic payloads with a targeted protein degrader, so the payload is only released inside antigen-positive cells. Early programmes target BRD4 and other essential proteins that are too toxic to degrade systemically. This is a route to attack undruggable but essential nuclear proteins that would otherwise be intolerable.
Shares Kymera Therapeutics, Nurix Therapeutics, Drugging the 'undruggable' cancer targets, The undruggable drivers.
Shares Kymera Therapeutics, Nurix Therapeutics, Drugging the 'undruggable' cancer targets, The undruggable drivers.
Shares Kymera Therapeutics, Drugging the 'undruggable' cancer targets, The undruggable drivers, PROTACs & molecular glues (targeted protein degradation).
Shares Kymera Therapeutics, Nurix Therapeutics, The undruggable drivers, PROTACs & molecular glues (targeted protein degradation).
Shares Drugging the 'undruggable' cancer targets, The undruggable drivers, PROTACs & molecular glues (targeted protein degradation).
Shares Drugging the 'undruggable' cancer targets, The undruggable drivers, PROTACs & molecular glues (targeted protein degradation).
Shares Degrader-antibody conjugate (DAC), PROTACs & molecular glues (targeted protein degradation).
Shares Bystander effect (ADC), Payload (ADC), Antibody-drug conjugate (ADC).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/